New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
07:09 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-APOCIIIRx
Isis Pharmaceuticals announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. In this open-label study, three patients with FCS treated with ISIS-APOCIIIRx achieved substantial reductions in triglycerides with all three patients achieving a triglyceride level below 500 mg/dL, which substantially reduces the risk of an acute pancreatitis event. In addition, significant reductions in chylomicrons were observed that correlated with reductions in triglyceride levels.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
09:03 EDTISISIsis Pharmaceuticals reports Q2 EPS 29c, consensus 29c
Subscribe for More Information
August 3, 2015
17:06 EDTISISIsis reports FOCUS FH Phase 3 study met primary efficacy endpoint
Isis Pharmaceuticals (ISIS) announced that the FOCUS FH phase 3 study of KYNAMRO in patients with severe heterozygous familial hypercholesterolemia met its primary efficacy endpoint, a statistically significant reduction in LDL-cholesterol after 60 weeks of treatment of once weekly injections of 200 mg of KYNAMRO compared to placebo. LDL-cholesterol reduction was similar to that observed in previous phase 3 studies. In addition, based on the data available for review, the safety profile of KYNAMRO observed in the FOCUS FH trial was similar to the safety profile reported in previous phase 3 studies. Genzyme (SNY) will provide a more in depth review of the safety and efficacy data at a future medical meeting.
05:39 EDTISISIsis Pharmaceuticals and AstraZeneca collaborate to develop antisense drugs
Isis Pharmaceuticals (ISIS) and AstraZeneca (AZN) announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney. AstraZeneca will pay an upfront fee of $65M to Isis Pharmaceuticals plus development and regulatory milestones for each program that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each program. This transaction is subject to clearances under the Hart-Scott Rodino Antitrust Improvements Act.
July 31, 2015
17:31 EDTISISIsis Pharmaceuticals cuts stake in Regulus to 5.57%
Subscribe for More Information
July 29, 2015
17:13 EDTISISIsis announces publication of Phase 2 clinical results from volanesorsen study
Isis Pharmaceuticals and Akcea Therapeutics, its wholly owned subsidiary, announced that the New England Journal of Medicine has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen, formerly ISIS-APOCIIIRx, in patients with very high to severely high triglycerides. This publication follows the December 2014 publication in the New England Journal of Medicine of the positive Phase 2 results from a clinical study of volanesorsen in patients with familial chylomicronemia syndrome. Volanesorsen is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics.
July 27, 2015
10:40 EDTISISIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
07:07 EDTISISIsis Pharmaceuticals announces results from ISIS-TTRRx study
Subscribe for More Information
July 22, 2015
19:26 EDTISISIsis Pharmaceuticals announces positive clinical data of ISIS-APO(a)Rx published
Subscribe for More Information
July 21, 2015
07:13 EDTISISIsis Pharmaceuticals initiates Phase 1/2a clinical study of ISIS-HTT Rx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use